Breakthrough: FDA Approves 29 New Orphan Drugs in 2023

Rare diseases have become a focal point for major pharmaceutical companies. In 2022, the FDA's Center for Drug Evaluation and Research (CDER) approved 37 new drugs, with 18 of them specifically targeting rare diseases, accounting for 49% of the approvals. In 2023, the trend continued with the approval of 55 new drugs, out of which 29 were orphan drugs, representing a record-breaking 53% of the total approvals. This article explores the significant advancements in the field of orphan drugs and highlights the key findings from the FDA's approvals in 2023.

Unveiling the Orphan Drug Landscape:

The 29 orphan drugs approved by the FDA in 2023 comprised of 19 small molecule drugs and 10 biologics. These drugs targeted a diverse range of conditions, with rare oncology drugs leading the way, accounting for 35% of the approvals. The neurology domain followed closely, representing over 20% of the approvals. Combined, these two areas accounted for more than half of the total orphan drug approvals. Other therapeutic areas, including immunology, metabolism, infectious diseases, orthopedics, and specific inflammations, also witnessed new drug approvals.

Key Players and Emerging Biotech Companies:

Multinational pharmaceutical giants such as Pfizer, Eli Lilly, Johnson & Johnson, and Novartis remained at the forefront of orphan drug development, accounting for half of the approved drugs. Pfizer, for instance, had two drugs, Ngenla and Elrexfio, enter the market. However, emerging biotech companies like Reata Pharmaceuticals, Ionis Pharmaceuticals, Amicus Therapeutics, and Catalyst Biosciences played an increasingly important role in orphan drug research and development. Notably, the approval of Loqtorzi, a novel biologic developed through collaboration between Junshi Biosciences and Coherus, marked a significant milestone as the first innovative biologic independently researched and produced in China, targeting nasopharyngeal cancer.

Potential Blockbusters in the Making:

The forecast for orphan drug sales in 2023 indicates that 12 out of the newly approved drugs have the potential to achieve peak sales exceeding $500 million. Among them, five drugs are projected to surpass $1 billion in peak sales. Notable contenders include Talvey by Johnson & Johnson ($5 billion), Fabhalta by Novartis ($3.6 billion), Jaypirca by Eli Lilly ($1 billion), Omvoh by Eli Lilly ($1.2 billion), and Pombiliti by Amicus Therapeutics ($1.2 billion). Furthermore, Rystiggo is predicted to reach sales of $990 million by 2031, while Skyclarys ($740 million), Filspari ($713 million), Wainua ($700 million), Daybue ($650 million), Ojjaara ($627 million), Ogsiveo ($544 million), Elrexfio ($536 million), and Junshi's Loqtorzi ($200 million) are expected to achieve peak sales exceeding $500 million.

The FDA's approval of 29 new orphan drugs in 2023 signifies a remarkable milestone in rare disease treatments. The increasing focus on rare diseases by pharmaceutical companies, the diverse therapeutic areas targeted by these drugs, and the emergence of biotech companies as key contributors highlight the commitment to addressing unmet clinical needs. With potential blockbusters on the horizon, these approvals bring hope to patients and reinforce the significance of ongoing research and development efforts in the field of orphan drugs.